Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane by P.A. Corsetto et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Effects of n-3 PUFAs on breast cancer cells through their incorporation in
plasma membrane
Lipids in Health and Disease 2011, 10:73 doi:10.1186/1476-511X-10-73
Paola A Corsetto (paola.corsetto@unimi.it)
Gigliola Montorfano (gigliola.montorfano@unimi.it)
Stefania Zava (stefania.zava@unimi.it)
Ilaria E Jovenitti (ilaria.jovenitti@unimi.it)
Andrea Cremona (andrea.cremona@unimi.it)
Bruno Berra (not@valid.com)
Angela M Rizzo (angelamaria.rizzo@unimi.it)
ISSN 1476-511X
Article type Research
Submission date 6 April 2011
Acceptance date 12 May 2011
Publication date 12 May 2011
Article URL http://www.lipidworld.com/content/10/1/73
This peer-reviewed article was published immediately upon acceptance. It can be downloaded,
printed and distributed freely for any purposes (see copyright notice below).
Articles in Lipids in Health and Disease are listed in PubMed and archived at PubMed Central.
For information about publishing your research in Lipids in Health and Disease or any BioMed
Central journal, go to
http://www.lipidworld.com/info/instructions/
For information about other BioMed Central publications go to
http://www.biomedcentral.com/
Lipids in Health and Disease
© 2011 Corsetto et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Effects of n-3 PUFAs on breast cancer cells through their 
incorporation in plasma membrane 
Paola A. Corsetto, Gigliola Montorfano, Stefania Zava, Ilaria E. Jovenitti, Andrea Cremona, 
Bruno Berra1, Angela M. Rizzo§ 
 
Dipartimento di Scienze Molecolari Applicate ai Biosistemi, Università degli Studi di Milano, 
Italy. 
 
1 Passed away in April 2010 
§ Corresponding author Angela Maria Rizzo, Dipartimento di Scienze Molecolari Applicate 
ai Biosistemi, Università degli Studi di Milano, Via D. Trentacoste 2, 20134 Milan, Italy. 
Phone: +39 02 503 15777.Fax: +39 02 503 15775 
E-mail:  angelamaria.rizzo@unimi.it 
paola.corsetto@unimi.it 
gigliola.montorfano@unimi.it 
stefania.zava@unimi.it 
ilaria.jovenitti@unimi.it 
andrea.cremona@unimi.it 
 
 
 
 
 
Abstract  
Background 
PUFAs are important molecules for membrane order and function; they can modify 
inflammation-inducible cytokines production, eicosanoid production, plasma 
triacylglycerol synthesis and gene expression. Recent studies suggest that n-3 PUFAs 
can be cancer chemopreventive, chemosuppressive and auxiliary agents for cancer 
therapy. Ν−3 PUFAs could alter cancer growth influencing cell replication, cell cycle, 
and cell death. The question that remains to be answered is how n-3 PUFAs can affect 
so many physiological processes. We hypothesize that n-3 PUFAs alter membrane 
stability, modifying cellular signalling in breast cancer cells.  
Methods 
Two lines of human breast cancer cells characterized by different expression of ER 
and EGFR receptors were treated with AA, EPA or DHA. We have used the MTT 
viability test and expression of apoptotic markers to evaluate the effect of PUFAs on 
cancer growth. Phospholipids were analysed by HPLC/GC, to assess n-3 
incorporation into the cell membrane.  
Results 
We have observed that EPA and DHA induce cell apoptosis, a reduction of cell 
viability and the expression of Bcl2 and procaspase-8. Moreover, DHA slightly 
reduces the concentration of EGFR but EPA has no effect. Both EPA and DHA 
reduce the activation of EGFR. 
N-3 fatty acids are partially metabolized in both cell lines; AA is integrated without 
being further metabolized. We have analysed the fatty acid pattern in membrane 
phospholipids where they are incorporated with different degrees of specificity. N-3 
PUFAs influence the n-6 content and vice versa. 
Conclusions 
Our results indicate that n-3 PUFA feeding might induce modifications of breast 
cancer membrane structure that increases the degree of fatty acid unsaturation. This 
paper underlines the importance of nutritional factors on health maintenance and on 
disease prevention. 
 
Background 
Breast cancer is the most common cancer among women worldwide, with an 
estimated 1.4 million new breast cancer cases only in 2008. Epidemiologic and 
experimental studies suggest that dietary fatty acids influence the development and 
subsequent progression of breast cancer [1-3]. The role that long-chain n-3 
polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA, 20:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3), play in the aetiology of cancer has been 
highlighted by animal experiments and in vitro studies [4, 5]. A number of 
mechanisms have been proposed for the anticancer actions of n-3 PUFAs. The most 
prominent mechanism for the chemopreventive action of n-3 PUFAs is their 
suppressive effect on the production of arachidonic acid (AA)-derived prostanoids, 
particularly prostaglandin E2 (PGE2), which has been implicated in the immune 
response to inflammation, cell proliferation, differentiation, apoptosis, angiogenesis 
and metastasis [6].  
The n-3 PUFAs might alter the growth of tumour cells by influencing cell replication, 
by interfering with components of the cell cycle or by increasing cell death either by 
way of necrosis or apoptosis [7, 8]. For example, these fatty acids are involved in 
regulating the tumour p53 proapoptotic signal and superoxide dismutase (SOD) 
levels, telomere shorting and tumour angiogenesis [9]. In vitro treatment with DHA 
arrested cell-cycle progression in human-derived breast cancer and malignant 
melanoma cells [10, 11]. Similarly, in vitro treatment with EPA is reported to arrest 
the growth of K-562 human leukemic and many other cancer cells accompanied by 
down-regulation of cyclin expression in some instances [12, 13, 14]. 
In addition, recent studies of human breast cancer have shown that n-3 PUFAs up-
regulate syndecan 1 (SDC-1), which has been shown to play a role in cell adhesion 
[15, 16], inhibit matrix metalloproteinases [17] and decrease invasion of tumour cells. 
SDC-1 induces apoptosis in myeloma cells and some studies suggest a similar 
property in breast cancer cells [18, 19]. The transcriptional pathway for the n-3 PUFA 
regulation of SDC-1 expression involves the nuclear hormone receptor peroxisome 
proliferator-activated receptor gamma (PPARγ) [20]. Moreover n-3 PUFAs down-
regulate the expression of HER2/neu, a well characterized oncogene that plays a key 
role in aetiology, progression and chemosensitivity of various types of human cancer 
in which this oncogene is over-expressed. HER2/neu encodes transmembrane 
tyrosine kinase orphan receptor p185Her2/neu, which regulates biological functions 
including cellular proliferation, differentiation, motility and apoptosis [21]. 
Nevertheless the mechanism by which n-3 PUFAs inhibit the growth of breast cancer 
cells is not well understood, but it has been suggested that these fatty acids might 
change the fluidity and structure of the cell membrane. In fact, changes in the 
structural characteristics of the plasma membrane in mammalian cells can modify the 
activity of proteins that function as ion channels, transporters, receptors, signal 
transducers or enzymes [21-25].  
In this study, we have investigated the impact of EPA, DHA and AA on breast cancer 
cell growth, on cell signalling in apoptosis and on epidermal growth factor receptor 
(EGFR) activity. We hypothesize that the alteration of cellular cycle, of gene 
expression and the induction of apoptosis determined from n-3 PUFAs are also a 
consequence of membrane architecture modifications. For these reasons we have 
analyzed PUFA incorporation in breast cancer membrane and their PL-specific 
enrichment.  
Methods 
Cell lines and culture conditions 
Human breast cancer cell lines MDA-MB-231 (ER-negative) and MCF-7 (ER-
positive) were kindly provided by Dr P. Degan from the IST (Italian National Cancer 
Research Institute, Genoa Italy, Laboratory of Molecular Mutagenesis and DNA 
Repair). Both cell lines are derived from human mammary adenocarcinoma; the 
MCF7 line retains several characteristics of differentiated mammary epithelium, 
including the ability to process estradiol via cytoplasmic estrogen receptors. The 
MDA-MB-231 cells over-express EGFR. 
These cell lines were maintained in DMEM (Gibco-BRL, Life Tecnologies Italia srl, 
Italy) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 
mg/ml streptomycin and 2 mM glutamine.  
Medium for treatments (MFT) was DMEM supplemented with 10% FBS. Cells were 
grown at 37°C in a 5% CO2 atmosphere with 98% relative humidity. 
PUFAs 
EPA (cis-5,8,11,14,17-eicosapentaenoic acid sodium salt), DHA (cis-4,7,10,13,16,19-
docosahexaenoic acid sodium salt) and AA (arachidonic acid sodium salt) were 
purchased from Sigma-Aldrich, USA. The PUFAs were dissolved in ethanol and 
stored at –80°C under nitrogen gas.  
Antibodies 
The mouse monoclonal anti-Bcl2 antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA) and the C20 goat polyclonal anti-procaspase-8 p18 antibody were 
used to study the n-3 PUFA induction of the apoptosis process. The 1005 rabbit 
polyclonal anti-EGFR antibody and the 11C2 mouse monoclonal anti-pEGFR 
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) were used to 
investigate the alterations of EGFR receptors after treatment with PUFAs. The 
monoclonal anti-actin (AC-40) antibody (Sigma-Aldrich, USA) was used to 
normalize gel loading.  
Bound primary antibodies were visualized by secondary horseradish peroxidase 
(HRP)-linked antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and 
immunoreactivity was assessed by chemiluminescence (ECL, Amersham). 
Cell viability assay 
The numbers of viable cells exposed to fatty acids were evaluated by the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay [26]. 
Initially, cells were seeded and cultured in 96-well plates for 48 h to allow adhesion 
to the plate and to reach 50–60% confluence. After this period, the culture medium 
was changed to the experimental medium supplemented with EPA or DHA or AA 
then cultured for 72 h. We studied the effects of different concentrations of PUFAs 
(50–300 µM). The final concentration of ethanol (<1%) in the culture medium had no 
antiproliferative effect on any cell line tested; therefore, 10 µl of MTT stock solution 
(5 mg/ml in PBS, pH 7.5) was added to each well and incubated for 4 h as a control. 
Then 100 µl of solubilizing solution (10% SDS in 0.01M HCl) was added and 
incubated overnight. Plates were read at 540 nm in a plate reader. All reagents were 
purchased from Sigma-Aldrich, USA. Data points represent the mean of eight wells 
and the results are expressed as relative growth rate (RGR) in comparison to controls 
that were exposed to a concentration of ethanol equal to that in the samples exposed 
to fatty acids.  
Cell treatment 
Cell culture experiments were done with the MDA-MB-231 and MCF-7 cell lines to 
determine the concentrations of EPA (230 µM), DHA (200 µM), required to inhibit 
growth by 20–30%, and AA (200 µM). Cells were seeded at 1.5 × 104 cells/cm2 for 
MDA-MB-231 and at 3 × 104 cells/cm2 for MCF-7 in 18 ml of medium containing 
10% FBS and allowed to adhere for 48 h, then the medium was replaced with 18 ml 
of fresh medium (DMEM, 10% FBS) containing the experimental fatty acids and 
incubated for 72 h without changing the medium. Experiments included untreated 
cells that were not exposed to any exogenous fatty acids but to an equal content of 
ethanol during the incubation to serve as controls. After 72 h, cells were harvested 
using trypsin-EDTA and centrifuged at 900 rpm for 10 min. The supernatant was 
removed and the pellets were subjected to lipid analysis. 
For western blot analysis, cells were harvested by scraping in phosphate-buffered 
saline containing 0.4 mM Na3VO4. Cells were centrifuged and then suspended in 1.4 
ml of lysis buffer (1% Triton X-100, 10 mM Tris buffer, pH 7.5, 150 mM NaCl, 5 
mM EDTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 75 mU/ml 
aprotinin), kept on ice for 20 min and then disrupted by 10 strokes in a tight-fitting 
Dounce homogenizer. The cell lysate was centrifuged (5 min at 1300g) and the 
supernatant was transferred to an eppendorf tube. Total protein was determined by the 
Lowry assay [27]. 
Lipid composition analysis  
Cell lipids were extracted with three different chloroform/methanol mixtures (1:1, 1:2 
and 2:1, v/v) and partitioned with a theoretical upper phase 
(chloroform/methanol/water, 47:48:1, by vol.) and then with water. The organic phase 
was dried and then suspended in chloroform/methanol (2:1, v/v) for the analysis of 
total and PL fatty acids. 
Purification of single PL moieties was achieved with an HPLC-ELSD system (Jasco, 
Japan) equipped with one pump, a SCL-10 Advp, a degasser module and a Rheodyne 
manual injector with 20 µl sample loop and a column (length 250 mm, I.D 4.6 mm 
and film thickness 5 µm) packed with silica normal-phase LiChrospher Si 60 
(LiChroCART 250-4, Merck, Darmstadt, Germany). 
The chromatographic separation was achieved with a linear binary gradient of 0% B 
to 100% B in 14 min and then 100% B for 9 min. The total chromatographic run time 
was 40 min/sample; 23 min analysis, 12 min to restore initial conditions and 5 min for 
re-equilibration. Eluent A was chloroform/methanol/water (80:19.5:0.5, by vol.) and 
eluent B was chloroform/methanol/water (60:34:6, by vol.) and the flow rate of the 
eluent was 1.0 ml/min. An evaporative light-scattering detector (ELSD) was used to 
detect and quantify the separated PL species. 
After elution, the eluate was split with one part going to the detector and nine parts to 
a Gilson fraction collector model 201 to collect the different PL classes for GC 
analysis.  
Total fatty acids and PL fatty acids were determined as methylesters by gas 
chromatography (GC). The methyl esters were obtained by reaction with 3.33% (w/v) 
sodium methoxide in methanol and injected into an Agilent Technologies (6850 
series II) gas chromatograph equipped with a flame ionization detector (FID) and a 
capillary column (AT Silar) (length 30 m, film thickness 0.25 µm). The carrier gas 
was helium, the injector temperature was 250°C, the detector temperature was 275°C, 
the oven temperature was set at 50°C for 20 min and then increased to 200°C at 10°C 
min–1 for 20 min. 
Western blot analysis for Bcl2, caspase-8, EGFR and pEGFR 
Control and treated cell lysates (100 µg protein/lane) were separated by SDS-PAGE 
(10% polyacrylamide gel), transferred to a polyvinylidene difluoride (PVDF) 
membrane and analysed by western blot with anti-Bcl2 (1:100), anti-caspase-8 
(1:500) and β-actin (1:1800) antibodies. The PVDF membrane was blocked for 1 h in 
blocking buffer 5% (w/v) dried non-fat milk in Tris-buffered saline (T-TBS: 10 mM 
Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween®20) followed by incubation 
with an appropriate primary antibody in blocking buffer at room temperature for 2 h. 
The blots were washed with T-TBS and then incubated with the proper secondary 
antibody in blocking buffer at room temperature for 1 h. The protein bands were 
visualized using ECL western blot detection reagents (PerkinElmer, USA). 
For the analysis of EGFR and p-EGFR, cells treated or not with DHA and EPA were 
cultured in MFTs supplemented with 10 nM EGF (Sigma-Aldrich, St. Louis, MO, 
USA) and incubated at 37°C for 15 min of stimulation. Cells were washed twice with 
ice-cold phosphate-buffered saline (PBS) and lysed as described above. Equal 
amounts of protein (100 µg/lane) from each treatment were separated by SDS-PAGE 
(10% polyacrylamide gel) and transferred onto a PVDF membrane then blocked in 
blocking buffer at room temperature for 1 h. Primary antibodies to EGFR and p-
EGFR were diluted 1:200 in blocking buffer at room temperature for 2 h and then 
with an appropriate secondary antibody at room temperature for 1 h. Parallel blots 
were probed under the same conditions with primary antibody β-actin diluted 1:1800 
to confirm equal protein loading. 
The relative intensities of band signals were determined by digital scanning 
densitometry and β-Actin was used to normalize the results to protein content. 
 
Statistical analysis 
The data are presented as mean ± SD. Student’s unpaired t-test was used for 
comparisons between treated and control cells and the level of statistical significance 
was set at P <0.05 and P <0.01. 
 
 
RESULTS 
The effects of treatment with PUFAs on breast cancer cell growth 
To evaluate the effects of PUFAs on breast cancer proliferation, cells were incubated 
for 3 days in medium supplemented with n-3 and n-6 PUFAs (EPA, DHA and AA).  
The effect on cell viability of MDA-MB-231 and MCF7 cells was assessed and 
quantified by the MTT assay. As shown in Fig. 1, cells were treated with various 
concentrations of n-3 and n-6 PUFAs in the range 50–300 µM.  
DHA and EPA induce a dose-dependent reduction of cell viability at concentrations > 
200 µM (Fig. 1A and 1B).  
In contrast, AA (Fig. 1C), the major n-6 PUFA, had no significant effect on MCF7 
cell viability. The MCF7 cell line was more resistant than the MDA-MB-231 cell line 
to all treatments with PUFAs.  
From these experiments, we extrapolated the dose to be used in successive 
experiments to assess n-3 PUFA incorporation into cell membrane PLs: 230 µM for 
EPA, 200 µM for DHA, which correspond to 70~80% viability for both cell lines, 
and 200 µM for AA. 
DHA and EPA induce apoptosis in breast cancer cells 
In order to delineate the possible mechanism(s) by which EPA and DHA induce 
apoptosis we examined the cytoplasmic levels of the Bcl2 protein. Figure 2A and 
2B indicate that there was a slight reduction of Bcl2 level in MCF7 cells after 
treatment with 200 µM DHA, whereas treatment with 230 µM EPA determined the 
loss of signal; the expression of Bcl2 is also decreased when MDA-MB-231 cells are 
treated with 230 µM EPA and the protein is not detectable after incubation with 200 
µM DHA.  
Furthermore, apoptosis involves the activation of procaspase-8 (55 kDa) by its 
cleavage to caspase-8 (18 kDa); this smaller protein together with caspase-3 
mediates the rapid dismantling of cellular organelles and architecture [28].  
The expression of procaspase-8 was determined by western blot analysis. In Fig. 3A 
and 3B it is possible to observe a reduction of the proform of caspase-8 for both cell 
lines treated with EPA and DHA; the reduction was statistically significant after 
DHA treatment in both cell lines, and also after EPA treatment of MCF7 cells.  
EPA and DHA alter the EGFR and pEGFR levels in MDA-MB-231 cells 
EGFR is usually activated in response to extracellular ligands (EGF) by its 
phosphorylation; ligand binding leads to homo- or heterodimerization with another 
ligand-bound ErbB receptor, and transmits extracellular mitogenic signals to 
downstream target signalling cascades that involve cell survival and proliferation, 
such as phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein kinase 
(MAPK) and signal transducer and activator of transcription 3 (STAT3) [29]. 
In human breast cancer cell lines, such as MDA-MB-231, the EGFR level is elevated 
compared with that in other breast cancer cells, such as MCF7 [30]; for this reason, 
we have studied the effects of DHA and EPA on EGFR activity mainly in MDA-
MB-231 cells. 
Figure 4 reports the effects of EPA and DHA treatments on expression and 
activation of EGFR in presence of EGF. EPA did not modify EGFR expression in 
breast cancer cells; while EGF stimulation significantly increase EGFR 
phosphorylation to about 140%; co-treatment with EPA/EGF significantly inhibit 
EGFR activation down to about 40% compared to control non stimulated cells (Fig. 
4A). 
As shown in Fig. 4B, DHA significantly reduces the EGFR level (70%) compared to 
control cells and completely inhibit EGFR activation in cells treated with DHA or 
DHA/EGF.  
Total fatty acid profile after treatment with PUFA  
Treatment with AA, EPA or DHA alters the FA profile in MDA-MB-231 and MCF7 
cells compared with control cells (Table 1).  
Treatment of both cell lines with AA resulted in a significant increase of AA content 
in total cell lipids, from 14.40% to 46.85% in MDA-MB-231 and from 12.73% to 
44.26% in MCF7. Furthermore, the data for MDA-MB-231 show a significant 
decrease of EPA, docosapentaenoic acid (DPA) and DHA, whereas the data for 
MCF7 cells show a significant reduction of only EPA and DHA.  
When both cell lines were treated with EPA, the content of this FA in total cell lipids 
was increased significantly and we observed a significant reduction of AA. 
Unexpectedly, we found an increase of DPA content, indicating that EPA is 
incorporated into cells and is further metabolized by elongation.  
The treatment with DHA determines a significant increase of DHA content in both 
cell lines and an increase of EPA content in MCF7, probably due to a retro 
conversion; a significant reduction of AA content was also measured. 
Effects of treatment with PUFAs on PL composition in breast cancer cells 
Table 2 and 3 give the fatty acid composition of specific PLs in MDA-MB-231 and 
MCF7 cells treated with n-3 or n-6 PUFAs; to simplify the tables SD, are reported as 
plain numbers above the bold mean value. 
After treatment with AA, the content of this n-6 PUFA was increased significantly in 
PE and PC in MDA-MB-231 (Fig. 5, Table 2). The treatment induced a reduction of 
omega-3 PUFAs, particularly EPA, that was significantly decreased in all 
phospholipids but SM; while DHA content was decreased after AA treatment only in 
PE and PC,  the other two omega- 3 fatty acids namely DPA and ALA (C18:3) were 
decreased in all phospholipids but SM. 
Incubation with EPA caused an increase of EPA content in all PLs in MDA-MB-231 
cells. In particular, the incorporation of EPA was different in relation to the PL 
moiety with highest levels of incorporation in PI and PC. There was a decrease of 
monounsaturated FA in PE and PC, and a significant increase of polyunsaturated FA 
in PI and PC. Furthermore, an increase of DPA content was found in all PLs, 
especially PC. The content of AA was significantly decreased in all phospholipids 
but SM.  
After treatment of MDA-MB-231 cells with DHA, the content of this fatty acid was 
significantly increased in all cell membrane PLs, but not in SM.  
We measured a significant decrease of the content of EPA in PE, PS, PI and PC. The 
concentration of AA was significantly reduced in PE and PI and SM as the result of 
treatment with DHA.  
In MCF7 cells (Fig. 6, Table 3), the treatment with AA induced a significant 
increase of this fatty acid in all PLs, except in SM; a significant reduction of EPA 
and of DHA in PE, PI, PS and PC was also measured.  
After treatment with EPA, the EPA and DPA content was significantly increased, 
especially in PE, PI, PS and PC. The concentration of DHA was significantly 
decreased in PE and PI, whereas the AA content was significantly reduced in PE, 
and PI.  
The exposure of MCF7 cells to DHA determined a significant increase of DHA in all 
PLs, but not in SM, and of EPA content in PE, PI, and  PC, whereas the content of 
AA was significantly reduced only in PE, PI and PS. 
Also in these cells a significant decrease of monounsaturated fatty acids is always 
present when the cells are treated with n-6 and n-3 PUFAs; while saturated fatty 
acids are in most cases constant. 
Moreover also 18:2, 18:3 (n-3) and 20:3 (n-6) are significantly decrease after PUFA 
treatment. 
As far as phospholipids content concerns, it is worth noting the significant decrease 
of SM content (from 11.32% to 9.02%, data not shown) in MCF7 after treatment 
with DHA even if, sphingomyelin is the phospholipid less influenced in its fatty acid 
composition by PUFA treatment. The other treatments did not modify the 
distribution of PL in both cell lines. 
DISCUSSION 
Breast cancer is the leading cause of the death among women in the world. The 
principal effective endocrine therapy for treatment on this type of cancer is anti-
estrogens, but therapeutic choices are limited for estrogen receptor (ER) negative 
tumor, which are more aggressive. Moreover the development of ER positive cancer 
cells that are resistant to chemotherapeutic agents is a major factor responsible to the 
successful treatment of breast cancer. This is a strong input to discover new 
approaches in vitro.  
Several epidemiologic and clinical studies have shown that n-3 PUFAs are able to 
provide beneficial effects in a wide variety of pathologies ranging from autoimmune 
and inflammatory diseases to neurological and psychiatric disorders and, in particular, 
to several types of malignancy, including ovarian, pancreatic, prostate, renal, 
colorectal and breast cancer [31-33].    
This study was prompted by the observation that MDA-MB-231 and MCF7 breast 
cancer cell lines showed a significant reduction in cell number following treatment 
with n-3 PUFAs. The same conclusion is not possible for the AA incubation. We 
hypothesize that this reduction in cell number results from both proliferation 
reduction and induction of apoptosis. Apoptosis is a genetically controlled form of 
cell death that is conserved from worms to humans. Deregulation of apoptosis is a 
hallmark of all cancer cells and the agents that activate apoptosis in cancer cells could 
be considered as anti-cancer therapeutics [34]. In some mammalian cells, apoptosis 
can be triggered by members of the Fas/TNF receptor family. When activated by 
receptor aggregation, Fas and TNFR1 induce the activation of a set of cysteine 
proteases called caspases. Studies designed to elucidate the mechanism(s) by which 
Fas and TNFR1 stimulation lead to caspase activation are underway. In the case of 
Fas, receptor aggregation by the Fas ligand induces the formation of a death-inducing 
signalling complex (DISC) of proteins comprising Fas itself, the adaptor protein 
FADD and the inactive zymogen form of caspase-8. Shortly after formation of the 
DISC, procaspase-8 is cleaved and the active protease is released. Once activated, 
caspase-8 is thought to activate other downstream caspases by proteolytic cleavage of 
their zymogen forms, thus amplifying the caspase signal [35]. Our results 
demonstrate the activation of caspase-8 in response to incubation with n-3 PUFAs by 
a reduction of the levels of its zymogen form in both cell lines. In many cells, over-
expression of either Bcl2 or Bcl-xl inhibits apoptosis, affecting the release of cyt-c 
and apoptosis-inducing factor (AIF) from the mitochondrial intramembrane space to 
the cytosol. Once released, AIF is translocated to the nucleus where it is capable of 
inducing nuclear chromatin condensation and large-scale DNA fragmentation that 
mediates a caspase-independent mitochondrial apoptotic pathway [36]. Cyt-c, 
together with dATP, binds to apoptotic proteinase activating factor-1 (Apaf-1) and 
this complex promotes procaspase-9 autoactivation. The active forms of caspase-8 
and caspase-9 might activate the downstream effectors caspase-3, -6 and -7, resulting 
in the cleavage of crucial cellular proteins and apoptosis. We have observed a 
significant difference in the amount of Bcl2 present in the DHA-treated MDA-MB-
231 cells and EPA-treated MCF7 cells compared to the control group. The absence of 
Bcl2 when compared to the control is suggestive that the cell might be more likely to 
proceed to apoptosis.                                                                                           
EGFR is an interesting target for tumour therapy, because it is over-expressed in 
many human tumours such as lung and breast cancers [37]. MDA-MB-231 cells 
express high levels of EGFR and are a good model to study EGFR modulation by n-3 
PUFAs. This receptor is a member of the ErbB receptor tyrosine kinase family, which 
consists of EGFR (or HER1 or ErbB1), HER2/ErbB2, HER3/ErbB3 and HER4/ErbB. 
Ligand binding to EGFR induces its dimerization with another EGFR or with other 
members of the ErbB family, and activates tyrosine kinase residues on the 
intracellular domains of the protein through autophosphorylation.                                                                               
EGFR recruits downstream signalling proteins, triggering signal cascades along a 
number of pathways that eventually lead to cell growth, migration and apoptosis 
resistance [38, 39]. We found that the phosphorylated EGFR levels are reduced after 
treatment with n-3 PUFAs (EPA or DHA) in MDA-MB-231 cells, whereas the EGFR 
level was decreased only after incubation with DHA. 
The entire mechanism by which n-3 PUFAs exert their beneficial effects is not fully 
understood. We have hypothesized that the induction of apoptosis, the reduction of 
cell proliferation and the inhibition of EGFR activity by these fatty acids might be the 
consequences of cell membrane alterations induced by FA. Our data indicate that 
EPA and DHA are incorporated in breast cancer membrane. In particular the EPA 
treatment determines an increase of EPA and DPA content, and a reduction of SFA, 
MUFA and n-6 PUFA concentration in both cell lines. This suggests an incorporation 
of EPA which is further metabolised. In fact, EPA is converted to 22:5 n-3 (DPA) by 
elongase (Elovl)-5 and then by Elovl-2 to 24:5, n-3. The next step requires 
desaturation of 24:5 by ∆6 desaturase to produce 24:6, n-3. This product is 
translocated from the endoplasmic reticulum to the peroxisome, where the β 
oxidation pathway involves acyl chain shortening of C2 to produce DHA [40]. 
Also DHA incubation determines an increase of EPA, of DHA, and in general of the 
unsaturation degree in both cell lines. We have also observed that PUFAs are 
incorporated into the breast cancer membrane with different specificity for each PL 
moiety. The enrichment is significant, especially in PE, PI and PC. The transbilayer 
distribution of lipids across biological membranes is asymmetric. The choline-
containing lipids PC and SM are enriched primarily on the external leaflet of the 
plasma membrane or the topologically equivalent luminal leaflet of internal 
organelles. In contrast, the amine-containing glycerophospholipids PE and PS are 
located preferentially on the cytoplasmic leaflet. Other minor PLs, such as 
phosphatidic acid (PA), PI and phosphatidylinositol-4,5-bisphosphate (PIP2) are also 
enriched on the cytofacial side of the membrane. Specific alterations of the molecular 
composition of the plasma membrane occur during apoptosis. Hence, cells 
undergoing apoptosis express signals, including lipids, proteins and modified sugar 
moieties that facilitate recognition and ingestion by macrophages. Loss of 
transmembrane PL asymmetry, with consequent exposure of PS in the external 
monolayer, occurs in both normal and pathologic conditions. PS externalization is 
induced early in the process of apoptosis. On the basis of our findings, the data 
suggest that the incorporation of n-3 PUFAs is mainly into cytofacial leaflet PLs, 
altering the membrane environment to impact on the activation of cell signalling. 
Moreover, a significant decrease of SM was evident in cells treated with DHA. 
Once lipid asymmetry has been established, it is maintained by a combination of 
slow transbilayer diffusion, protein–lipid interactions and protein-mediated transport. 
The most significant contributors to the maintenance and dissipation of transbilayer 
lipid asymmetry are proteins that catalyse the movement of lipids across the 
membrane. Two classes of transport activities have been described that are 
responsible for the ATP-dependent transport of lipids. The best characterized activity 
is flippase, which transports PS from the outer monolayer to the cytoplasmic surface 
of the plasma membrane and requires ATP and Mg2+ but its activity is inhibited by 
Ca2+. A second ATP-dependent activity, catalysed by flippases, transports lipids in 
the opposite direction. The third class of lipid transporter consists of the Ca2+-
activated scramblases that catalyse the PS externalization [41, 42]. Growing 
evidence indicates that excessive concentrations of FA affect cell functions by 
altering the activity of various ion transporters and channels, including Ca2+. Zhang 
et al. have found that PUFAs, but not monounsaturated or saturated FAs, cause 
[Ca2+]i mobilization in NT2 human tetracarcinoma cells by causing release of this 
proton from mitochondria [43]. Furthermore, Djemli-Shipkolye et al. showed that 
FA modifications in membranes could be correlated with the variations observed in 
the activity of ATPase, for instance of Mg-ATPase [44]. This effect could influence 
the flippase and scramblase activities, and thus the transbilayer lipid asymmetry.  
Moreover PUFA incorporation induces an alteration of SFA, MUFA and PUFA 
content in membrane phospholipids; these data suggest a metabolic rearrangement in 
cells in order to try to balance the ratio between saturated and unsaturated fatty acids.  
In addition membranes constitute a meeting point for lipids and proteins. Thousands 
of cellular proteins interact with membranes in different ways, for example integral 
(transmembrane, as EGFR) proteins are embedded in the lipid bilayer and their 
activity is sensitive to changes in the lipid environment. Recently, multiple studies 
demonstrated very rapid ERα actions at level of the plasma membrane [45]. 
O’Malley and collaborators have demonstrated that ERα on the membrane initially 
activates cytoplasmic kinases, which in turn phosphorylate and activate coactivators 
proteins in the cytoplasm. These coactivators then travel to the nucleus and modulate 
ERα-mediated transcriptional events [46].  
Then n-3 PUFAs, modifying the unsaturated degree, the permeability, the flip-flop 
process and the fluidity of the plasma membrane, might alter the activity of these 
proteins. This hypothesis will be investigated in our laboratory. 
 
5. CONCLUSIONS 
We suggest that n-3 PUFAs induce modifications of membrane structure and 
function of breast cancer cells, thereby increasing the degree of unsaturation. These 
changes of plasma membrane might modify the membrane architecture and signal 
transduction causing a reduction of cell proliferation and apoptosis induction. 
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Figure Legends 
Figure 1  - Effects of PUFA on viability of breast cancer cells 
The effect on cell viability of PUFA in MDA-MB-231 and MCF7 cells is assessed 
and quantified by MTT assay. Cells are treated with various concentrations of EPA 
(A), DHA (B), and AA (C). Cells are seeded and cultured for 48 h in a 96-well plate, 
after this period, the medium is replaced with fresh medium for treatments with AA, 
EPA, or DHA and incubated for further 72 h. The numbers of viable cell exposed to 
fatty acids are evaluated by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Data represent the mean of eight values 
and results are expressed as Relative Growth Rate (RGR) in comparison with controls 
(100%). * p<0.05; ** p<0.01 compared to control cells. 
 
Figure 2  - Effects of n-3 PUFA on Bcl2  expression  
Both cell lines were treated with DHA (200 µM) or EPA (230 µM) for 72 h.  Control 
and treated cell lysates are separated on 10% SDS-PAGE and transferred to PVDF 
membrane.  
A: The expression of the anti-apoptotic protein Bcl2 was assessed by western blot.  
B: Semi-quantitative analysis performed by plate scanning. β actin was used to 
normalize results of protein content. 
Figure 3  - Effects of n-3 PUFAs on caspase-8 expression . 
The determination of the integrity of the procaspase-8 after treatment with DHA (200 
µM) and EPA (230 µM) for 72 h was assessed in both cell lines. 
A: MCF7 cells treated with DHA (200 µM) or EPA (230 µM) for 72 h . 
B: MDA-MB-231 cells treated with DHA (200 µM) or EPA (230 µM) for 72 h   
Semi-quantitative analysis performed by plate scanning. β-actin was used to 
normalize results of protein content. ** p<0.01 compared to control cells; n=3 
Figure 4  - EGFR expression and EGF stimulation (p-EGFR) in MDA-MB-231 
breast cancer cells after n-3 PUFAs treatment 
A: MDA-MB-231 treated with 230 µM EPA for 72 h, lane 1 control, lane 2 230 µM 
EPA, lane 3 EGF, lane 4 EGF+EPA.  
B: MDA-MB-231 treated with 200 µM DHA for 72 h, lane 1 control, lane 2 200 µM 
DHA, lane 3 EGF, lane 4 EGF+DHA. 
The relative intensities of band signals, reported in graphics, are determined by digital 
scanning densitometry. β-actin was used to normalize results of protein content. * 
p<0.05; ** p<0.01 compared to control cells; n=3. 
Figure 5  - Content of AA (C20:4), EPA (C20:5), DPA (20:6), DHA (C22:6), SFA 
and MUFA in PLs of MDA-MB-231 cells treated with LCPUFAs 
MDA-MB-231 cells were treated with AA, EPA, and DHA. Purification of single PL 
moieties was achieved with an HPLC-ELSD system. PL fatty acids were determined 
as methyl esters by gas chromatography (GC). Data are reported as percentage of 
total fatty acids. Controls are not exposed to any exogenous fatty acids. * p<0.01; 
n=3. 
Figure 6  - Content of AA (C20:4), EPA (C20:5), DPA (20:6), DHA (C22:6), SFA 
and MUFA in PLs of MCF7 cells treated with LCPUFAs 
MCF7 cells were treated with AA, EPA, and DHA. Purification of single PL moieties 
was achieved with an HPLC-ELSD system. PL fatty acids were determined as methyl 
esters by gas chromatography (GC). Data are reported as percentage of total fatty 
acids. Controls are not exposed to any exogenous fatty acids. * p<0.01; n=3. 
  
0
50
100
150
50 100 150 200 220 240 260 280 300
EPA ( M)
R
G
R
 (
%
) 
MDA
MCF7
  **
**
**
*
**
**
**
**
 
 
0
50
100
150
50 100 150 200 220 240 260 280 300
DHA ( M)
R
G
R
 (
%
) *
**
**
** **
**
**
**
** ****
 
 
0
50
100
150
50 100 150 200 250 300
AA ( M)
R
G
R
 (
%
)
** **
 
A
B 
C 
Figure 1
Bcl2 MCF7
0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
 
 
Bcl2 MDA-MB-231
0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
 
A                 MCF7
Bcl2
く-actin 
B             MDA-MB-231 
CTR        EPA    CTR    DHA
Bcl2 
く-actin 
CTR        EPA      CTR      DHA      
Figure 2
    CTR   EPA  CTR  DHA  
Procaspase-8 MCF7
0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
****
 
CTR     EPA   CTR  DHA 
Procaspase-8 MDA-MB-231
0
20
40
60
80
100
120
EPA DHA
CTR
TREATMENT
**
 
B MDA-MB-231
-actin
ProCASPASE 8 
ProCASPASE 8 
A   MCF7 
-actin 
Figure 3
  
 
 
 
 
 
EGFR
0
50
100
CTR EPA EGF EGF/EPA
EGFR 
0
50
100
CTR DHA EGF EGF/DHA
**
 
p-EGFR 
0
50
100
150
CTR EPA EGF EGF/EPA
*
**
p-EGFR
0
50
100
150
CTR DHA EGF EGF/DHA
*
 
 
EGF CTR DHA DHA/EGF      B 
pEGFR 
EGFR 
-actin 
CTR EGF EPA/EGF EPA 
pEGFR 
EGFR 
-actin 
     A 
Figure 4
PE MDA
0
10
20
30
40
50
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
*
*
*
*
*
PE MDA 
0
10
20
30
SFA MUFA
 CTR
 AA
 EPA
 DHA*
*
*
*
PI MDA
0
10
20
30
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
* *
*
*
*
* *
*
*
*
*
PI MDA
0
10
20
30
40
50
60
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
PS MDA
0
10
20
30
40
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
*
*
PS MDA
0
10
20
30
40
50
60
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
PC MDA
0
10
20
30
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
*
*
PC MDA
0
10
20
30
40
50
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
*
*
SM MDA
0
2
4
6
8
10
12
14
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
SM MDA
0
10
20
30
40
50
60
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
 
Figure 5
PE MCF7
0
10
20
30
40
50
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
*
*
 *
PE MCF7
0
10
20
30
40
50
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
PI MCF7
0
10
20
30
40
50
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
*
*
*
*
*
*
*
*
PI MCF7
0
10
20
30
40
50
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
*
**
PS MCF7
0
10
20
30
40
50
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
 *
*
*
*
*
*
*
PS MCF7
0
10
20
30
40
50
SFA MUFA
 CTR
 AA
 EPA
 DHA
*
*
*
*
PC MCF7
0
10
20
30
40
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
*
*
* *
*
PC MCF7
0
10
20
30
40
50
SFA MUFA
 CTR
 AA
 EPA
 DHA
* *
*
*
* *
SM MCF7
0
10
20
30
C20:4 C20:5  C 22:5  C 22:6
 CTR
 AA
 EPA
 DHA
*
 *
SM MCF7
0
10
20
30
40
50
60
SFA MUFA
 CTR
 AA
 EPA
 DHA*
*
 
Figure 6
